Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
New Nordic Healthbrands AB's 3-Year RORE % for the quarter that ended in Mar. 2026 was -140.46%.
The industry rank for New Nordic Healthbrands AB's 3-Year RORE % or its related term are showing as below:
FRA:N9X's 3-Year RORE % is ranked worse than 93.71% of 1829
companies
in the Consumer Packaged Goods industry
Industry Median: 6.02
vs FRA:N9X: -140.46
New Nordic Healthbrands AB (FRA:N9X) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
New Nordic Healthbrands AB 3-Year RORE % Related Terms
New Nordic Healthbrands AB 3-Year RORE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:N9X vs KHC, GIS, HRL: 3-Year RORE % Comparison
For the Packaged Foods subindustry, New Nordic Healthbrands AB's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
New Nordic Healthbrands AB 3-Year RORE % vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, New Nordic Healthbrands AB's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where New Nordic Healthbrands AB's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
New Nordic Healthbrands AB (FRA:N9X) has a 3-Year RORE % of -140.46 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on New Nordic Healthbrands AB and its competitors. According to the industry distribution chart, New Nordic Healthbrands AB ranks #1714 out of 1829 companies in the Consumer Packaged Goods industry, placing it in the top 93.7%.
Is New Nordic Healthbrands AB's 3-Year RORE % too high?
New Nordic Healthbrands AB's current 3-Year RORE % is -140.46. Based on the distribution chart, New Nordic Healthbrands AB ranks #1714 out of 1829 companies in the Consumer Packaged Goods industry, which is in the bottom quartile relative to peers. Overall, New Nordic Healthbrands AB has a GF Score™ of 59/100, reflecting its overall financial health beyond just this single metric.
How does New Nordic Healthbrands AB's 3-Year RORE % compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, New Nordic Healthbrands AB ranks #1714 out of 1829 companies for 3-Year RORE %. This places New Nordic Healthbrands AB in the lower half of its industry. The industry median 3-Year RORE % is 6.02. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Consumer Packaged Goods company?
The median 3-Year RORE % among Consumer Packaged Goods companies is 6.02, based on 1,829 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on New Nordic Healthbrands AB and its competitors. For the Consumer Packaged Goods industry, the median 3-Year RORE % is 6.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. New Nordic Healthbrands AB's current 3-Year RORE % is -140.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is New Nordic Healthbrands AB stock overvalued right now?
New Nordic Healthbrands AB (FRA:N9X) has a current 3-Year RORE % of -140.46. The stock's GF Value™ is €1.73, compared to a current price of €1.03 — trading 40.5% below its estimated fair value. The current 3-Year RORE % is -140.46. New Nordic Healthbrands AB's overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For New Nordic Healthbrands AB (FRA:N9X), the current 3-Year RORE % is -140.46 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is New Nordic Healthbrands AB (FRA:N9X) Overvalued in 2026?
Based on GuruFocus' analysis, New Nordic Healthbrands AB stock appears to be undervalued.
The current stock price of €1.03 is trading 40.5% below its estimated GF Value™ of €1.73.
Key valuation signals for FRA:N9X:
3-Year RORE %: -140.46
GF Value™: €1.73 vs. price of €1.03 (40.5% below fair value)
No single metric tells the full story. See the FRA:N9X stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
New Nordic Healthbrands AB develops herbal supplements, herbal remedies, and personal care products to satisfy specific health and beauty needs. The products are sold in North America, Europe, and Asia. Some products sold are Active legs, Active Liver, Apple Cider, Chili Burn, Clear brain, Ear tone, Equazen, Frutin gastro gel, Hair Gro, Hair Volume, Kilo trim, and Melissa Dream. Maximum revenue is generated from the Nordic region.
59GF Score
Get the complete analysis for FRA:N9X
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:N9X has been successfully added to your 
